Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed

Technology appraisal guidance
Reference number: TA375
Published: 26 January 2016

History

Appeal

Appeal
NICE scrutiny letter to MSD : Scrutiny letter (PDF 38 KB)

Published:

26 November 2015
NICE scrutiny letter to MSD : Scrutiny letter (PDF 102 KB)

Published:

26 November 2015
BSR response to initial scrutiny letter : Response to scrutiny letter (PDF 237 KB)

Published:

26 November 2015
MSD response to initial scrutiny letter : Response to scrutiny letter (PDF 50 KB)

Published:

26 November 2015
NRAS response to initial scrutiny letter : Response to scrutiny letter (PDF 48 KB)

Published:

26 November 2015
BSR Appeal letter : Appeal letter (PDF 433 KB)

Published:

26 November 2015
MSD Appeal letter : Appeal letter (PDF 156 KB)

Published:

26 November 2015
NRAS Appeal letter : Appeal letter (PDF 589 KB)

Published:

26 November 2015
NICE final scrutiny letter to BSR : Final scrutiny letter (PDF 84 KB)

Published:

26 November 2015
NICE final scrutiny letter to MSD : Final scrutiny letter (PDF 21 KB)

Published:

26 November 2015
NICE scrutiny letter to BSR : Scrutiny letter (PDF 100 KB)

Published:

26 November 2015
Appeal decision (PDF 391 KB)

Published:

26 January 2016

Final appraisal determination

Final appraisal determination information
Final appraisal determination document
Final appraisal determination document (PDF 668 KB)

Published:

03 September 2015
Committee papers information
Committee papers (PDF 4.79 MB)

Published:

03 September 2015

Appraisal consultation

Appraisal consultation
Appraisal consultation document
Appraisal consultation document (PDF 818 KB)

Published:

19 June 2015
Committee papers information
Committee papers (appendices 1-3)
Committee papers (appendices 1-3) (PDF 10.87 MB)

Published:

19 June 2015
Committee papers (appendices 4-11)
Committee papers (appendices 4-11) (PDF 9.49 MB)

Published:

19 June 2015
Committee papers (appendix 12)
Committee papers (appendix 12) (PDF 10.14 MB)

Published:

19 June 2015
Committee papers (appendices 13-19)
Committee papers (appendices 13-19) (PDF 6.48 MB)

Published:

19 June 2015

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment report addendum

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: appendix 1 updated assessment report

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: appendix 1 updated assessment report
Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: appendix 1 updated assessment report (PDF 12.08 MB)

Published:

17 March 2015

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: decision support unit report

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment group report

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment report

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment report
Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: assessment report (PDF 9.51 MB)

Published:

04 September 2013

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: institutes response to consultees and commentator comments on the draft scope and provisional matrix (replacement)

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: institutes response to consultees and commentator comments on the draft scope and provisional matrix (replacement)
Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: institutes response to consultees and commentator comments on the draft scope and provisional matrix (replacement) (PDF 377 KB)

Published:

22 February 2013

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: final protocol

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: final protocol
Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: final protocol (PDF 589 KB)

Published:

30 November 2012

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: final scope

Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: final scope
Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review: final scope (PDF 55 KB)

Published:

30 November 2012

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: equality impact assessment - scoping

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: equality impact assessment - scoping
Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: equality impact assessment - scoping (PDF 15 KB)

Published:

22 November 2012

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: final scope (superseded)

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: final scope (superseded)
Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: final scope (superseded) (PDF 94 KB)

Published:

09 November 2012

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: final matrix

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: final matrix
Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review: final matrix (PDF 34 KB)

Published:

09 November 2012

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review [ID537]: provisional matrix

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review [ID537]: provisional matrix
Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review [ID537]: provisional matrix (PDF 42 KB)

Published:

16 August 2012

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review [ID537]: draft scope

Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review [ID537]: draft scope
Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review [ID537]: draft scope (PDF 137 KB)

Published:

14 August 2012